News & Updates
Filter by Specialty:
Cefepime–taniborbactam bests meropenem for complicated UTI
Patients with complicated urinary tract infection (UTI) may fare better with cefepime–taniborbactam than with meropenem, with the combination having been associated with much higher treatment success rates in the phase III CERTAIN-1 trial.
Cefepime–taniborbactam bests meropenem for complicated UTI
10 Mar 2024Severe COVID-19 rare in PrEP-treated SARDs patients
Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.
Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024Pulse vs nonpulse corticosteroid: Which is better against IPF?
Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) who received a pulse dose of corticosteroids do not appear to have longer survival than those who received conventional nonpulse dose of corticosteroids, results of a study have shown.